Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Medi-first Pep-t-med
Generic Name
Bismuth Subsalicylate
Active Ingredient
Bismuth SubsalicylateCategory
Bismuth [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 262 mg/1 | TABLET, CHEWABLE | ORAL | 47682-406 |
Detailed information about Medi-first Pep-t-med
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Medi-first Pep-t-med, you must consult a qualified healthcare professional.
Bismuth subsalicylate is a versatile gastrointestinal agent used to treat diarrhea, heartburn, and upset stomach. It belongs to the bismuth-containing antidiarrheal and mucosal protective class.
For the treatment of acute diarrhea or upset stomach, the standard adult dosage of bismuth subsalicylate is typically 524 mg (two 262 mg tablets or 30 mL of regular strength liquid) every 30 to 60 minutes as needed. It is critical not to exceed 8 doses (4,192 mg) in a 24-hour period. For the prevention of traveler's diarrhea, healthcare providers may suggest 524 mg four times daily for up to three weeks during travel. In the context of H. pylori eradication, the dosage is often 525 mg taken four times daily (with meals and at bedtime) for 10 to 14 days, usually as part of a multi-drug regimen. Always use a calibrated measuring device for liquid forms to ensure accuracy.
Bismuth subsalicylate is generally NOT recommended for children or teenagers who have or are recovering from viral infections, such as chickenpox or the flu, due to the risk of Reye's syndrome. For children over the age of 12, the adult dosage is typically followed. For children ages 9 to 12, the dose is often 262 mg every 30-60 minutes, not to exceed 8 doses in 24 hours. For children under 9, you must consult a pediatrician before administration. Many pediatricians recommend 'Children's Pepto,' which often contains calcium carbonate instead of bismuth subsalicylate, specifically to avoid the salicylate risk.
Patients with significant kidney disease (renal impairment) should use bismuth subsalicylate with extreme caution. Since the salicylate component is cleared by the kidneys, impaired function can lead to toxic accumulation of salicylate in the blood. Consult your doctor for specific guidance if your GFR (glomerular filtration rate) is below 60 mL/min.
While bismuth itself is not metabolized by the liver, the salicylate component is conjugated in the liver. Patients with severe hepatic impairment or cirrhosis may have altered metabolism and should consult a healthcare provider before use to avoid metabolic imbalances.
Elderly patients are at a higher risk for salicylate-induced side effects, such as tinnitus (ringing in the ears) and gastrointestinal bleeding. Lower doses or less frequent administration may be advisable, and close monitoring of kidney function is recommended.
If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to 'catch up,' as this increases the risk of salicylate toxicity.
Signs of a bismuth subsalicylate overdose may include extreme thirst, rapid breathing, ringing in the ears (tinnitus), confusion, seizures, or severe dizziness. If an overdose is suspected, contact a Poison Control Center (1-800-222-1222 in the US) or seek emergency medical attention immediately. Treatment usually involves gastric lavage (stomach pumping), activated charcoal, and supportive care to manage electrolyte imbalances.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or continue use for more than two days without medical guidance, as prolonged use can mask underlying serious conditions.
The most distinctive and common side effect of bismuth subsalicylate is a temporary darkening of the tongue and stool. This occurs because bismuth reacts with trace amounts of sulfur in your saliva and gastrointestinal tract to form bismuth sulfide. Bismuth sulfide is a highly insoluble black salt. This effect is completely harmless and will disappear once you stop taking the medication. Patients often mistake the black stool for melena (bloody stool), but bismuth-induced stool is typically non-tarry and lacks the foul odor of digested blood. Another common side effect is mild constipation, as the medication works to slow intestinal motility.
> Warning: Stop taking Bismuth Subsalicylate and call your doctor immediately if you experience any of these serious symptoms.
Bismuth subsalicylate is not intended for long-term daily use. Prolonged use (weeks to months) can lead to bismuth toxicity. The primary concern with long-term use is accumulation in the central nervous system and kidneys. Chronic salicylate exposure can also lead to 'salicylism,' characterized by chronic tinnitus, headache, and metabolic acidosis (too much acid in the body). If you find yourself needing BSS for more than two weeks, you must consult a gastroenterologist to rule out chronic conditions like Inflammatory Bowel Disease (IBD) or Celiac disease.
There are currently no FDA black box warnings specifically for bismuth subsalicylate. However, the FDA requires a strong 'Reye's Syndrome' warning on all salicylate-containing products. This warning emphasizes that children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. If changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but fatal illness.
Report any unusual symptoms to your healthcare provider. Your safety is paramount, and even 'harmless' side effects like black tongue should be discussed if they cause anxiety or persist after discontinuation.
Bismuth subsalicylate is a safe and effective medication for most adults when used as directed for short periods. However, because it contains salicylate (the same active component found in aspirin), it carries specific risks for certain populations. It is not a simple 'stomach coater'—it is a pharmacologically active compound that interacts with the body's inflammatory and metabolic pathways. Patients should be aware that BSS can interfere with certain diagnostic tests, such as X-rays of the abdomen, because bismuth is radiopaque (it shows up on the X-ray and can block the view of other organs).
No FDA black box warnings for Bismuth Subsalicylate. However, the Reye's Syndrome Warning is the most critical safety precaution associated with this drug. Reye's syndrome is a devastating disease that causes acute encephalopathy (brain dysfunction) and liver fatty infiltration. It has a high mortality rate and is strongly linked to the use of salicylates during viral illnesses in youth.
For short-term OTC use, routine lab monitoring is generally not required. However, for patients on Bismuth Quadruple Therapy for H. pylori, or those with underlying health issues, healthcare providers may monitor:
Bismuth subsalicylate does not typically cause drowsiness or cognitive impairment at standard doses. It is generally considered safe to drive or operate machinery while taking this medication. However, if you experience rare side effects like dizziness or tremors, avoid these activities and contact your doctor.
While there is no direct chemical interaction between bismuth and alcohol, consuming alcohol while you have an upset stomach or diarrhea can worsen your symptoms and lead to further dehydration. Furthermore, chronic heavy alcohol use increases the risk of gastrointestinal bleeding, which can be further exacerbated by the salicylate component of BSS.
There is no need to taper bismuth subsalicylate; you can stop taking it as soon as your symptoms resolve. There is no known withdrawal syndrome. However, if your symptoms return immediately after stopping, this suggests an underlying issue that requires a professional medical diagnosis.
> Important: Discuss all your medical conditions with your healthcare provider before starting Bismuth Subsalicylate, particularly if you have a history of asthma, nasal polyps, or kidney disease.
For each major interaction, the mechanism usually involves either protein binding displacement (salicylates pushing other drugs off albumin) or chelation (bismuth binding to other drugs). The clinical consequence is often increased toxicity of the interacting drug or reduced efficacy of an antibiotic. Management usually involves spacing doses or avoiding the combination entirely.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous drug-drug interactions.
Bismuth subsalicylate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare provider include:
Patients who are sensitive to sulfites should check the inactive ingredients of liquid BSS formulations, as some may contain preservatives that trigger reactions. There is also a cross-sensitivity between BSS and other salicylates like salsalate, diflunisal, and oil of wintergreen (methyl salicylate). If you have reacted to any of these substances, you should avoid bismuth subsalicylate.
> Important: Your healthcare provider will evaluate your complete medical history, including allergies and chronic conditions, before prescribing or recommending Bismuth Subsalicylate. Never assume an OTC product is safe for you without checking for contraindications.
Bismuth subsalicylate is generally approached with caution during pregnancy. It is often categorized as Category C (by older FDA standards) or handled with specific trimester-based warnings. During the first and second trimesters, it should only be used if the potential benefit justifies the potential risk to the fetus. During the third trimester, use is generally discouraged. Salicylates can cause the premature closure of the ductus arteriosus (a critical blood vessel in the fetal heart) and may lead to prolonged labor or increased bleeding risk for both the mother and the newborn during delivery. Always consult an obstetrician before using BSS while pregnant.
Salicylates are excreted into breast milk. While the amount absorbed from a few doses of BSS may be low, there is a theoretical risk of Reye's syndrome in the nursing infant if they are concurrently exposed to a viral illness. Most healthcare providers recommend using alternative antidiarrheals, such as loperamide, or antacids that do not contain salicylates while breastfeeding. If use is necessary, monitor the infant for any signs of bruising or unusual behavior.
As previously emphasized, the primary concern in pediatrics is Reye's syndrome. BSS is generally not approved for children under the age of 12 without direct medical supervision. For children who need gastrointestinal relief, 'Children's' versions of popular brands often substitute the bismuth subsalicylate with calcium carbonate. If a doctor does prescribe BSS for a child (e.g., for H. pylori), the dose must be strictly weight-based and the child must be monitored closely for any viral symptoms.
Patients over the age of 65 are at increased risk for adverse effects from bismuth subsalicylate. This population is more likely to have reduced renal clearance, making salicylate toxicity more common. Additionally, the elderly are more prone to gastrointestinal bleeding and are often taking multiple other medications (polypharmacy) that may interact with BSS, such as blood thinners or blood pressure medications. Geriatric patients should use the lowest effective dose for the shortest possible duration.
In patients with kidney disease, the salicylate component of BSS can accumulate rapidly. For those on dialysis, bismuth itself—though minimally absorbed—can eventually reach levels that are neurotoxic over long periods of time. Dosage adjustments are not standardized, but frequent use is contraindicated in patients with a creatinine clearance of less than 30 mL/min.
While the liver is not the primary route of elimination for bismuth, it is responsible for the metabolism of the salicylate portion. Patients with Child-Pugh Class B or C hepatic impairment may experience altered salicylate pharmacokinetics. These patients should be monitored for signs of acid-base imbalances or increased bleeding tendencies if BSS is used.
> Important: Special populations require individualized medical assessment. What is safe for a healthy adult may be dangerous for a child, a pregnant woman, or an elderly individual with kidney issues.
Bismuth subsalicylate is a complex molecule that acts locally in the gut and systemically through its absorbed components. At the molecular level, the bismuth moiety provides bactericidal activity by inhibiting the growth of common pathogens like Helicobacter pylori, Salmonella, and Shigella. It achieves this by disrupting bacterial protein synthesis and cell wall integrity. Bismuth also acts as an adsorbent, binding to enterotoxins produced by bacteria. The subsalicylate moiety, once hydrolyzed to salicylic acid, inhibits the enzyme cyclooxygenase (COX), which reduces the production of pro-inflammatory prostaglandins. This 'antisecretory' effect reduces the movement of water and electrolytes into the intestinal lumen, thereby treating diarrhea.
The onset of action for bismuth subsalicylate is relatively rapid, with many patients experiencing relief from indigestion or heartburn within 30 to 60 minutes. The antidiarrheal effect may take slightly longer, often requiring multiple doses over several hours to achieve maximum efficacy. The duration of effect for a single dose is typically 4 to 6 hours. Tolerance does not generally develop with short-term use, but the drug's efficacy is dependent on the presence of an acidic environment in the stomach to facilitate the hydrolysis of the BSS molecule.
| Parameter | Value |
|---|---|
| Bioavailability | <1% (Bismuth), >80% (Salicylate) |
| Protein Binding | 90% (Salicylate) |
| Half-life | 2–5 hours (Salicylate, dose-dependent) |
| Tmax | 0.5–2 hours (Salicylate) |
| Metabolism | Hepatic conjugation (Salicylate) |
| Excretion | Renal (Salicylate), Fecal (Bismuth) |
Bismuth subsalicylate is categorized as a bismuth-containing antidiarrheal and a mucosal protective agent. It is related to other bismuth salts like bismuth subcitrate and bismuth subgallate, though BSS is the most widely used in the United States. Within the therapeutic area of gastroenterology, it is distinct from opioid-like antidiarrheals (like loperamide) because of its antimicrobial and anti-inflammatory properties.
Common questions about Medi-first Pep-t-med
Bismuth subsalicylate is a versatile medication primarily used to treat temporary gastrointestinal discomforts including diarrhea, heartburn, indigestion, nausea, and upset stomach. It works by coating the stomach lining and reducing inflammation and fluid secretion in the intestines. Additionally, it is used as part of a combination therapy to eradicate *H. pylori* bacteria in patients with peptic ulcers. Many people also use it to prevent or treat traveler's diarrhea during international trips. It is available over-the-counter in various forms like liquids, chewable tablets, and caplets. Always consult a healthcare provider if symptoms persist for more than two days.
The most common side effect of bismuth subsalicylate is a harmless, temporary darkening of the tongue and stool, which occurs when bismuth reacts with sulfur in the digestive tract. Some patients may also experience mild constipation as the medication slows down bowel movements. Less frequently, individuals might notice a metallic taste in the mouth or mild abdominal cramping. These effects are generally not serious and resolve shortly after the medication is discontinued. However, if you experience ringing in the ears (tinnitus), this could indicate salicylate sensitivity and you should stop taking the drug. Always report persistent or worsening symptoms to your doctor.
While there is no specific chemical contraindication between bismuth subsalicylate and alcohol, it is generally advised to avoid alcohol when experiencing gastrointestinal distress. Alcohol can irritate the stomach lining and worsen symptoms like heartburn, nausea, and diarrhea. Furthermore, alcohol can contribute to dehydration, which is already a risk during diarrheal illnesses. Because BSS contains salicylate, which can thin the blood slightly, heavy alcohol use may also increase the risk of stomach bleeding. It is best to wait until your digestive symptoms have fully resolved before consuming alcoholic beverages. Consult your healthcare provider for personalized advice.
Bismuth subsalicylate is generally not recommended during the third trimester of pregnancy because the salicylate component can cause complications for the fetus and the mother. Specifically, it may lead to the premature closure of the ductus arteriosus in the fetal heart and increase the risk of bleeding during delivery. During the first and second trimesters, it should only be used under the direct guidance of a healthcare provider if the benefits outweigh the potential risks. Most doctors prefer safer alternatives for digestive issues during pregnancy, such as certain antacids or lifestyle modifications. Always discuss any medication use with your obstetrician to ensure the safety of your pregnancy. Never self-medicate for gastrointestinal issues while pregnant.
For symptoms like heartburn, indigestion, and nausea, bismuth subsalicylate often begins providing relief within 30 to 60 minutes of the first dose. Its effect on diarrhea may take a bit longer, as it needs to reach the lower intestines and reduce fluid secretion; most patients see improvement within 24 hours of starting treatment. If you are taking it as part of a multi-drug regimen for *H. pylori*, the bacteria eradication process takes 10 to 14 days of consistent use. If your symptoms do not improve after two days of over-the-counter use, you should stop the medication and contact a healthcare professional. It is intended for short-term relief, not chronic management. Consistent dosing according to the label is key to its effectiveness.
Yes, you can stop taking bismuth subsalicylate suddenly as it does not require a tapering period and does not cause withdrawal symptoms. Most people stop taking it as soon as their acute symptoms of diarrhea or upset stomach have resolved. However, if you are taking it as part of a prescribed regimen for an ulcer or *H. pylori* infection, it is crucial to finish the entire course even if you feel better. Stopping an antibiotic/bismuth regimen early can lead to treatment failure and antibiotic resistance. If you experience any adverse effects that make you want to stop, consult your doctor first. For general OTC use, simply discontinue use once you are symptom-free.
If you miss a dose of bismuth subsalicylate, you should take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this can increase the risk of salicylate toxicity and side effects like ringing in the ears. For treating diarrhea, the timing is often based on the frequency of your symptoms, so a 'missed dose' is less critical than with other medications. However, for *H. pylori* treatment, consistency is very important for success. If you miss multiple doses, contact your pharmacist or doctor for guidance.
There is no clinical evidence to suggest that bismuth subsalicylate causes weight gain. It is intended for short-term use and does not affect the metabolic processes or hormonal balances associated with weight changes. The medication is not absorbed significantly into the systemic circulation, other than the salicylate component, which also has no link to weight gain. If you notice sudden weight changes or swelling while taking this medication, it is likely due to another factor, such as fluid shifts from dehydration or an underlying medical condition. Always discuss unexpected weight changes with your healthcare provider. BSS is generally considered weight-neutral.
Bismuth subsalicylate can interact with several other medications, so caution is necessary. It should not be taken with aspirin or other salicylates due to the risk of toxicity. It can also interfere with the absorption of certain antibiotics like tetracyclines and quinolones, so doses should be spaced several hours apart. Additionally, it may increase the effect of blood thinners like warfarin, potentially increasing the risk of bleeding. It can also interact with medications for gout, diabetes, and arthritis. Because of these potential interactions, you should always provide your doctor or pharmacist with a full list of your current medications before starting BSS. They can help you manage timing and dosage to avoid complications.
Yes, bismuth subsalicylate is widely available as a generic medication and is often sold under various store brands. The generic versions are bioequivalent to the brand-name products (like Pepto-Bismol) and contain the same active ingredient in the same concentrations. You can find generic BSS in liquid, chewable tablet, and caplet forms. Choosing a generic version is typically a cost-effective way to treat the same symptoms with the same level of efficacy. When buying generic, always check the 'Drug Facts' label to ensure the active ingredient and dosage match what you are looking for. Your pharmacist can help you select a high-quality generic alternative.
Other drugs with the same active ingredient (Bismuth Subsalicylate)